In contrast, the greatest anti-cancer activities were seen with the E2 and P4 combination protocols that could provide a superlative alternative therapeutic strategy against CRC, possibly by ERβ and PGR-mediated androgen deprivation and inhibition of ERα-induced cancer progression. Here, ESR2 is linked to colorectal carcinoma.